Literature DB >> 6217345

Longevity and mortality in Down's syndrome.

M E Thase.   

Abstract

The life span of individuals with DS has gradually increased since the 1920s. The DS individual now has an average life expectancy of 35 years. Despite advances in the health care of the retarded and improvements in the quality of institutional care, the overall mortality rate remains elevated by five-fold. Specific mortality rates from respiratory diseases (particularly pneumonia), infectious diseases, congenital heart disease, leukaemia and neurological disorders are still substantially increased. Disorders of immunological functioning, particularly T-cell mediated, appear related to this increased vulnerability, although further research is necessary. The periods of highest risk are during infancy, when congenital heart disease, leukaemia and respiratory diseases are most lethal, and late adulthood, when Alzheimer-type dementia and declining immunological function appear to be significant factors.

Entities:  

Mesh:

Year:  1982        PMID: 6217345     DOI: 10.1111/j.1365-2788.1982.tb00144.x

Source DB:  PubMed          Journal:  J Ment Defic Res        ISSN: 0022-264X


  18 in total

1.  Heart and heart-lung transplantation in Down's syndrome. The lack of supportive evidence means each case must be carefully assessed.

Authors:  H Leonard; K Eastham; J Dark
Journal:  BMJ       Date:  2000-03-25

2.  Health conditions associated with aging and end of life of adults with Down syndrome.

Authors:  Anna J Esbensen
Journal:  Int Rev Res Ment Retard       Date:  2010

3.  Down's syndrome and the general practitioner.

Authors:  G Howells
Journal:  Occas Pap R Coll Gen Pract       Date:  1990-11

4.  Childhood deaths in Down's syndrome. Survival curves and causes of death from a total population study in Queensland, Australia, 1976 to 1985.

Authors:  J A Bell; J H Pearn; D Firman
Journal:  J Med Genet       Date:  1989-12       Impact factor: 6.318

5.  Postnatal lethality and cardiac anomalies in the Ts65Dn Down syndrome mouse model.

Authors:  Clara S Moore
Journal:  Mamm Genome       Date:  2006-10-03       Impact factor: 2.957

6.  The expression of CD18 is increased on Trisomy 21 (Down syndrome) lymphoblastoid cells.

Authors:  G M Taylor; A Williams; S W D'Souza; W D Fergusson; D Donnai; J Fennell; R Harris
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

7.  Maternal Choline Supplementation Alters Basal Forebrain Cholinergic Neuron Gene Expression in the Ts65Dn Mouse Model of Down Syndrome.

Authors:  Christy M Kelley; Stephen D Ginsberg; Melissa J Alldred; Barbara J Strupp; Elliott J Mufson
Journal:  Dev Neurobiol       Date:  2019-06-09       Impact factor: 3.964

8.  Basal ganglia calcification and psychosis in Down's syndrome.

Authors:  M E Thase
Journal:  Postgrad Med J       Date:  1984-02       Impact factor: 2.401

9.  Extrapyramidal features in advanced Down's syndrome: clinical evaluation and family history.

Authors:  P Vieregge; G Ziemens; M Freudenberg; A Piosinski; A Muysers; B Schulze
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

10.  Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome.

Authors:  Nicole Schupf; Bindu Patel; Deborah Pang; Warren B Zigman; Wayne Silverman; Pankaj D Mehta; Richard Mayeux
Journal:  Arch Neurol       Date:  2007-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.